Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
KISIMA-01: ATP128 and VSV-GP128 with Ezabenlimab in Stage IV Colorectal Cancer
NCT04046445Phase 1Active, not recruiting
- Sponsor
- AMAL Therapeutics
- Start
- Jul 2019
- Primary completion
- May 2025
- Modality
- Oncolytic Viruses, Recombinant Protein Vaccines, Peptide-based Cancer Vaccines
- Countries
- 4
01
Overview
Phase 1, open-label trial of ATP128 and VSV-GP128 in colorectal cancer (CRC) (8 arms), sponsored by AMAL Therapeutics. Primary endpoints: Incidence of treatment-emergent adverse events (AEs) and serious adverse events (SAEs) at 1 year and Progression-free survival at 6 months. Started Jul 2019; status: active, not recruiting.
02
Drugs
ATP128VSV-GP128
03
Conditions
colorectal cancer (CRC)
Beyond the preview
Go deeper on NCT04046445.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT04046445.